Article
Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry.
Digestive diseases (Basel, Switzerland) - 1 Jan 2024
Guerra Iván, Barros Francisco, Chaparro María, Benítez José M, Martín-Arranz María Dolores, de Francisco Ruth, Piqueras Marta, de Castro Luisa, Carbajo Ana Y, Bermejo Fernando, Mínguez Miguel, Gutiérrez Ana, Mesonero Francisco, Cañete Fiorella, González-Muñoza Carlos, Calvo Marta, Sicilia Beatriz, Alfambra Erika, Rivero Montserrat, Lucendo Alfredo J, Tardillo Carlos A, Almela Pedro, Bujanda Luis, van Domselaar Manuel, Ramos Laura, Fernández Sánchez María, Hinojosa Esther, Verdejo Cristina, Gimenez Anna, Rodríguez-Lago Iago, Manceñido Noemí, Pérez Calle José L, Moreno Mónica Del Pilar, Delgado-Guillena Pedro Genaro, Antolín Beatriz, Ramírez de la Piscina Patricia, Casanova María José, Soto Escribano Pilar, Martín Arranz Eduardo, Pérez-Martínez Isabel, Mena Raquel, García Morales Natalia, Granja Alicia, Boscá Watts Marta Maia, Francés Rubén, Fernández Cristina, Calafat Margalida, Roig-Ramos Cristina, Vera María Isabel, Carracedo Ángel, Domènech Eugeni, Gisbert Javier P
Abstract excerpt
INTRODUCTION: Risk factors for developing pancreatitis due to thiopurines in patients with inflammatory bowel disease (IBD) are not clearly identified. Our aim was to evaluate the predictive pharmacogenetic risk of pancreatitis in IBD patients treated with thiopurines. METHODS: We conducted an observational pharmacogenetic study of acute pancreatitis events in a cohort study of IBD patients treated with...
Read the complete abstract on PubMed